University of Limerick Institutional Repository

A systematic review and individual patient data network analysis of the residual symptom structure following cognitive-behavioral therapy and escitalopram, mirtazapine and venlafaxine for depression

DSpace Repository

Show simple item record

dc.contributor.author Whiston, Aoife
dc.contributor.author Lennon, Amy
dc.contributor.author Brown, Catherine
dc.contributor.author Looney, Chloe
dc.contributor.author Larkin, Eve
dc.contributor.author O'Sullivan, Laurie
dc.contributor.author Sik, Nurcan
dc.contributor.author Semkovska, Maria
dc.date.accessioned 2022-04-01T11:21:07Z
dc.date.available 2022-04-01T11:21:07Z
dc.date.issued 2022
dc.identifier.uri http://hdl.handle.net/10344/11172
dc.description peer-reviewed en_US
dc.description.abstract Objective: Consistent evidence suggests residual depressive symptomology are the strongest predictors of depression relapse following cognitive-behavioral therapy (CBT) and antidepressant medications (ADM’s). Psychometric network models help detecting and understanding central symptoms that remain post-treatment, along with their complex co-occurrences. However, individual psychometric network studies show inconsistent findings. This systematic review and IPD network analysis aimed to estimate and compare the symptom network structures of residual depressive symptoms following CBT, ADM’s, and their combination. Methods: PsycINFO, PsycArticles, and PubMed were systematically searched through October 2020 for studies that have assessed individuals with major depression at post-treatment receiving either CBT and/or ADM’s (venlafaxine, escitalopram, mirtazapine). IPD was requested from eligible samples to estimate and compare residual symptom psychometric network models post-CBT and post-ADM’s. Results: In total, 25 from 663 eligible samples, including 1,389 patients qualified for the IPD. Depressed mood and anhedonia were consistently central residual symptoms post-CBT and post-ADM’s. For CBT, fatigue-related and anxiety symptoms were also central post-treatment. A significant difference in network structure across treatments (CBT vs. ADM) was observed for samples measuring depression severity using the MADRS. Specifically, stronger symptom occurrences were present amongst lassitude-suicide post-CBT (vs. ADM’s) and amongst lassitude-inability to feel post-ADM’s (vs. CBT). No significant difference in global strength was observed across treatments. Conclusions: Core major depression symptoms remain central across treatments, strategies to target these symptoms should be considered. Anxiety and fatigue related complaints also remain central post-CBT. Efforts must be made amongst researchers, institutions, and journals to permit sharing of IPD. en_US
dc.language.iso eng en_US
dc.publisher Frontiers Media en_US
dc.relation.ispartofseries Frontiers in Psychiatry;13, article 746678
dc.rights This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission en_US
dc.subject depression en_US
dc.subject residual symptomology en_US
dc.subject cognitive-behavioral therapy (CBT) en_US
dc.subject antidepressants en_US
dc.subject network psychometrics en_US
dc.title A systematic review and individual patient data network analysis of the residual symptom structure following cognitive-behavioral therapy and escitalopram, mirtazapine and venlafaxine for depression en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.3389/fpsyt.2022.746678
dc.contributor.sponsor IRC en_US
dc.contributor.sponsor Analog Devices en_US
dc.relation.projectid EPSPG/2020/487) en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics